Primary urachal adenocarcinoma treated effectively with surgery and post operative chemoradiation therapy: Case Report with review of the literature.

Urachal carcinomas is a rare and aggressive tumor, accounting for less than 1% of all bladder cancers. We report a case of a 32-year-old man, with no past medical history, complaining of a total hematuria. The abdominal computed tomography scan revealed an exophytic mass of 3 cm on the dome of the bladder, extending to the urachus. The computed tomography scan of chest, abdomen and pelvis did not show neither regional or distant metastasis. Partial Cystectomy with umbilectomy was performed. Histopathology was in favor of urachal adenocarcinoma, classed pT3a, based on Sheldon's staging system, pT2b based on Mayo system, and pT2 based on Ontario system.

Chondrosarcoma of the parapharyngeal space: Case report and literature review of an extremely rare location.

Chondrosarcoma of the head and neck region is a rare disease, representing approximately 0.1% of all head and neck neoplasms. Parapharyngeal location is extremely rare and low-grade ones are even rarer. Surgery alone or followed by adjuvant radiotherapy is the treatment of choice. In this article, we report a case of a 67-year-old male with low-grade parapharyngeal chondrosarcoma who presented with a 3-month history of dysphagia. A cervical magnetic resonance imaging was performed that shows a well-defined mass located at the right parapharyngeal space, causing medial deviation of the mucosal space. Surgical resection of the tumor without neck dissection followed by adjuvant radiotherapy was undertaken with a favorable response. The purpose of this article is to add our case to the limited literature for good management of parapharyngeal chondrosarcomas.

Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting.

At the meeting of the American Society of Clinical Oncology (ASCO 2020), held this year virtually on May 29-31, investigators presented important practice changing findings in non-small cell lung cancer (NSCLC). In the early-stage resectable NSCLC, the key presentation was ADAURA study. This phase III clinical trial showed that the use of adjuvant osimertinib in stage IB-IIIA NSCLC patients harboring EGFR mutations had a clinically meaningful benefit. In locally advanced NSCLC, the recent studies investigated the role of immune checkpoint inhibitors (ICIs) administred early with or before concurrent chemoradiotherapy. In advanced-stage NSCLC with driver mutations, new targets and drugs were explored. The major step forward was the approval of personalized treatment in very uncommon genomic alterations, as RET fusions or MET mutations. In advanced NSCLC without targetable mutations, some new immunotherapy combination strategies have been presented. One of such combination was tiragolumab, an immune checkpoint inhibitor binding to TIGIT, evaluated with atezolizumab. There were also data from the Checkmate 227 and Checkmate 9LA trials that led to recent approvals.

Primary intrapulmonary malignant peripheral nerve sheath tumor: A rare case.

A rare case of malignant peripheral nerve sheath tumor (MPNST) was found in the lungs of a 68-year-old male patient. He was referred to our hospital because of visual disturbances, confusion, and headaches. Upon admission, a chest-Abdomen-Pelvis CT scan (CT scan of CAP) showed a right posterobasal pulmonary lesion process associated with liver metastases and a lytic lesion of the vertebral body of D3. Brain MRI (Magnetic Resonance Imaging) revealed secondary brain lesions above and below the tentorium. Image guided liver biopsy showed a suspicious site of malignancy. In the histopathological examination, a diagnosis of MPNST was established. A biological agent, Imatinib, was administered and the patient underwent cerebral radiotherapy. CT scan of CAP showed a partial tumor response according to Chun's criteria. Pre-existing literature indicates that MPNSTs with metastases to the brain are very rare and have a poor prognosis - survival after brain metastases would be about 10 months. Our case report agrees with the literature, as the disease stabilized with treatment up to 7 months, after which the patient was unreachable and our team lost track of him. Our case report appears to be one of the first cases of primary MPNST in the lungs with brain metastases.